argenex SE (NASDAQ:ARGX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

argenex SE (NASDAQ:ARGX) has been given a consensus rating of “Moderate Buy” by the twenty-four analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eighteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $986.7778.

ARGX has been the topic of several research reports. Wells Fargo & Company raised their price target on shares of argenex from $1,264.00 to $1,317.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Wall Street Zen downgraded shares of argenex from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Piper Sandler lifted their target price on shares of argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. DZ Bank upgraded argenex to a “strong-buy” rating in a report on Friday, December 19th. Finally, Zacks Research cut argenex from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 22nd.

Hedge Funds Weigh In On argenex

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Capital World Investors boosted its stake in argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after acquiring an additional 8,422 shares during the last quarter. M&T Bank Corp increased its position in shares of argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Morgan Stanley lifted its position in shares of argenex by 19.2% during the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after purchasing an additional 83,746 shares during the last quarter. Finally, Invesco Ltd. grew its stake in argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after purchasing an additional 331,489 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Price Performance

argenex stock opened at $844.41 on Friday. The company has a market cap of $52.25 billion, a price-to-earnings ratio of 36.26, a price-to-earnings-growth ratio of 0.73 and a beta of 0.37. argenex has a 12 month low of $510.05 and a 12 month high of $934.62. The stock’s 50-day moving average is $831.22 and its 200-day moving average is $805.88.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.